Nusano vs Regeneron
Side-by-side comparison of AI visibility scores, market position, and capabilities
Nusano is a Seattle-based startup developing a proprietary linear accelerator platform to produce uranium-free diagnostic and therapeutic radioisotopes for the radiopharmaceutical industry; raised $22M in 2022;
About
Nusano is a radioisotope production technology company founded in 2017 and headquartered in Seattle, Washington. The company has developed a proprietary high-current linear accelerator (linac) technology designed to produce diagnostic and therapeutic radioisotopes outside of the nuclear reactor supply chain. Conventional medical radioisotope production relies heavily on aging nuclear research reactors and uranium-based processes — creating chronic supply chain vulnerabilities that periodically cause shortages of critical isotopes like Tc-99m (used in millions of cardiac and oncology scans annually). Nusano's linac technology produces isotopes without uranium, offering pharmaceutical manufacturers and hospitals a more stable, reactor-independent supply alternative.
Tarrytown NY biopharma giant; creator of Dupixent (>$14B revenue), Eylea, and Kevzara. Velocity Genome platform drives fast antibody and bispecific drug discovery.
About
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized mouse technology that dramatically accelerates the discovery of human antibodies—and has used it to produce multiple best-in-class biologics across inflammatory, oncologic, and eye diseases.\n\nRegeneron's commercial portfolio is anchored by Dupixent (dupilumab), developed with Sanofi, which has become one of the best-selling drugs globally with over $14 billion in 2024 revenues, treating atopic dermatitis, asthma, COPD, and other type-2 inflammatory conditions. Additional key products include Eylea (aflibercept) for macular degeneration and PRALUENT for cardiovascular cholesterol lowering. The company's bispecific antibody pipeline, cancer vaccines in collaboration with BioNTech, and gene therapy programs represent its next growth wave.\n\nRegeneron reported over $14 billion in annual revenue in 2024 and maintains a world-class science culture, consistently ranking among the top companies for R&D productivity and employee satisfaction. Its Tarrytown campus houses more than 10,000 employees and remains a leading independent US biopharmaceutical innovator.
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.